SBP GROUP (01177) announced that its subsidiary will present 21 new research findings at the 2026 Chinese Society of Clinical Oncology (CSCO) Annual Meeting, including five oral presentations.

The studies will cover investigational drug TQB3454 (an IDH1 inhibitor) and several marketed products, including Anlotinib Capsules (brand name: Fukevi®), TQB2450 Injection (brand name: Andewei®), Ebgstem Alfa Injection (brand name: Yilishu®), and Penpulimab Injection (brand name: Annike®).

The research spans multiple therapeutic areas such as pancreatic cancer, lung cancer, renal cell carcinoma, gastrointestinal tumors, soft tissue sarcoma, thyroid cancer, and breast cancer.